Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.
Erik van den Berg, Memo Therapeutics CEO
July 1, 2026 07:12 AM EDT
Deals
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ayisha Sharma
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed…
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a…
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s…
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a…
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
Novartis to acquire ADC developer in a deal worth up to $1.5B
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
BridgeBio gets funding for drug launch; United buys into cell therapy
